Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Elpiscience Cleared for US Trials of Bispecific Immunotherapy in Solid Tumors

publication date: May 9, 2022

Shanghai Elpiscience was cleared to start US trials of a first-in-class bispecific antibody that targets two major immunosuppressive mechanisms in the tumor microenvironment. ES014 is an anti-CD39xTGF-β bispecific that simultaneously targets the CD39-adenosine and TGF-β pathways. Elpiscience will test the drug in patients with advanced solid tumors. An immunoncology company, Elpiscience now has five molecules in clinical trials including an CD39 monotherapy. One year ago, Elpiscience closed a $105 million Series C round to start US trials of its portfolio of 15 innovative molecules. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China